• July 11, 2019 - Healthline - How Smaller Labs Are Pushing the Research Envelope into Alzheimer's
• July 3, 2019 - Washington Post - "Alzheimer’s research is getting a reboot at small companies focused on the immune system"
• June 25, 2019 - STAT+ - The maddening saga of how Alzheimer's 'cabal' thwarted progress toward a cure for decades
• June 24, 2019 - Seeking Alpha - Pfizer and INmune Bio: Seeking The Blockade of Tumor Necrosis Factor Alpha For Alzheimer's Disease
• June 13, 2019 - Innovation&Tech - Alzheimer’s Research is Gaining Steam with New Clinical Trials
• April 30, 2019 - STAT - After amyloid failures, it's time to take a new tack for treating Alzheimer's
• April 24, 2019 - US News - We Need New Ideas for FIghting Alzheimer's
• April 15, 2019 - US News - Is Alzheimer's Hereditary?
• April 02, 2019 - Inmuno Oncology News - INB03 May Help Reverse Cancer’s Resistance to Immunotherapy, INmune Bio Co-founder Says
• March 05, 2019 - Select Science - This Novel, Non-Amyloid Approach to Alzheimer’s Therapy Could Vastly Improve Outcomes
• March 04, 2019 - Scientific American - For Alzheimer’s Sufferers, Brain Inflammation Ignites a Neuron-Killing “Forest Fire”
• February 22, 2019 - Onco'Zine - Diet and Cancer: What’s the Connection? 
• February 20, 2019 - Investing News INmune Bio Pursues Alzheimer’s Treatment in New Clinical Trial 
• February 19, 2019 - Everyday Health Does Chronic Inflammation Cause Dementia? 
• February 05, 2019 - Genetic Engineering & Biotechnology News Is Cancer Smarter Than We Are?
• February 05, 2019 - Money Inc. Bylines Mediterranean Diet: Sun, Sea, and Olive Oil
• February 01, 2019 - San Diego Business Journal Online From Little Known to IPO: INmune Bio Raises $8.16 Million in Trading Debut
• January 01, 2019 - Money Inc. Bylines Chronic Inflammation: Real Disease, Wrong Name
• January 01, 2019 - Scientific American Are We Innately Immune to Cancer?
• January 01, 2019 - TIPS (Cell Magazine) MDSC: The Most Important Cell You've Never Heard Of
• December, 2018 - Onco'Zine INmune Bio Receives Phase I Clinical Trial Authorization for Lead Product in Ovarian Cancer
• December, 2018 - BioSpace INmune Bio Granted Phase I Clinical Trial Authorization of Lead Product INKmune™ in Refractory and Recurrent Ovarian Cancer Patients
• December, 2018 - TIPS (Cell Magazine) MDSC: The Most Important Cell You've Never Heard Of
• December, 2018 - Money Inc. Bylines Immunotherapy and Checkpoint Inhibitors: Can They Be More Effective?
• November, 2018 - BioProcess International eBook: Partnerships in Immunotherapy
• October 31, 2018 - Diagnostics World News XtalPi, Qure.ai, Thermo Fisher Scientific, And More: News From October 2018
• October 01, 2018 - Select Science Hiding in Plain Sight: How to Break Through the Tumor Microenvironment Forcefield
• September 25, 2018 - Diagnostics World News uBiome, AliveCor, Ariel Precision Medicine, And More: News From September 2018
• September 11, 2018 - Health Professional Radio INmune Bio – Cancer Treatment with Patient’s Own Immune System
• September 01, 2018 - Genetic Engineering & Biotechnology News Cancer Mindset Shifts from Pathology to Immunology
• August 08, 2018 - YourTango: 7 Things That Happen To Your Body After You Turn 30
• August 03, 2018 - Healthcare Global: The shift to tumour-agnostic immunotherapies
• August 01, 2018 - PopSugar: How to Tell If You Have Chronic Inflammation: Experts Explain Why It Can Be So Dangerous
• July 24, 2018 - Clinical Leader: Phase 1 Trial Targets The Immune System, Not The Cancer
• June 04, 2018 - The Hill: Cutting costs could be the key to curing cancer
• May 24, 2018 - R&D Mag Clinical Trial Investigates Novel Innate Immune System Checkpoint Inhibitor for Solid Tumors
• May 24, 2018 - Pharma Journalist INmune Bio Initiates Phase 1 Clinical Trial Of INB03
• April 23, 2018 - STAT: Combination immunotherapy may have failed in the Incyte/Merck trial, but it's here to stay

The Investor Relations website contains information about INMB's business for stockholders, potential investors, and financial analysts. Disclaimer - For Informational Purposes Only - The company assumes no responsibility for the accuracy of reports prepared by outside third parties, nor does it endorse any of the projections, recommendations or conclusions made herein.